Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2022

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Treatment with chimeric antigen receptor-T cell (CAR-T) is successful in patients who have not responded to chemotherapy or bone marrow transplantation but it may provoke side effects and long-term complications. Early and specific side effects include cytokine release syndrome and neurological toxicity. In addition, there are also late side effects. The most prominent of which is bone marrow damage and lack of recovery of blood counts after treatment.

In this study, patients with prolong aplasia after CAR-T will recieve eltrombopag to enahnce bone marrow recovery.
Epistemonikos ID: fc7af9b44adbb75bd582e4c9d629ec2ef157a09e
First added on: May 10, 2024